Ok, so it's been 2 weeks since the company sent their request to the FDA for an EUA based on the M2M trial results. Over this amount of time, there just has to be stuff going on behind the scenes between the company, FDA and who knows who else, likely related to manufacturing of Leronlimab. Don't think that the FDA would issue an EUA or outright granting of approval without knowing the details of manufacturing, distribution, etc. Seems that if the FDA was going to require a Phase III, they would have done that by now.